Patient & Survivor Care
News from the FDA/CDC
FDA Approves New Bladder Cancer Drug
The FDA declined an initial approval for the combination in May 2023.
Commentary
CRC Screening in Primary Care: The Blood Test Option
Last year, I concluded a commentary for this news...
From the Journals
New Screening Protocol May Improve Prostate Cancer Detection
A new trial assesses a screening intervention that aims to reduce unnecessary diagnoses of prostate cancer but still catch relevant cancers and...
Conference Coverage
How Can Kidney Cancer Patients Benefit From New Combination Therapy?
Immunotherapy has expanded treatment options as an adjuvant and a first-line therapy in patients with renal cell carcinoma.
Conference Coverage
How Long Should Active Surveillance Last?
New data “suggest that meticulous follow-up is needed over a longer time” than previous studies have shown.
From the Journals
Why Lung Cancer Screening Is Not for Everyone
Many participants in a survey were unaware that further imaging or other types of tests could follow LDCT.
Conference Coverage
Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity
“We now have a definitive result in a robustly conducted trial that will take the field forward,” says an author of the new research.
Feature
What’s Driving the Higher Breast Cancer Death Rate in Black Women?
New research suggests that racial disparities in breast cancer are driven by more than socioeconomic factors.
From the Journals
Microbial Signature of KRAS-Mutated Colorectal Cancer Identified
Researchers use 16s rRNA sequencing to analyze stool samples from 94 patients with CRC.
From the Journals
Certain Women May Face Higher Risk for Second Breast Cancer
Two and a half percent of breast cancer survivors developed a second primary breast cancer, a new study shows.
From the Journals
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...